Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2 Tumor-Agnostic 1 NET 1 Endocrine 1

Conditions

Neuroendocrine Tumors 1

Interventions

lutetium Lu 177 dotatate 14 Specimen Handling 8 Magnetic Resonance Spectroscopy 8 Everolimus 8 cabozantinib 6 pembrolizumab 4 Nivolumab 4 olaparib 3 lenvatinib 3 X-Rays 3 Lutetium-177 3 Cyclophosphamide 3 177Lu-octreotide, DOTA(0)-Tyr(3)- 3 lanreotide 2 gallium Ga 68 dotatate 2 fludarabine phosphate 2 fludarabine 2 avelumab 2 amino-acid, glucose, and electrolyte solution 2 Sunitinib 2 Phantoms, Imaging 2 Octreotide 2 Ipilimumab 2 Fluorodeoxyglucose F18 2 3-aminopyridine-2-carboxaldehyde thiosemicarbazone 2 tivozanib 1 surufatinib 1 repotrectinib 1 peposertib 1 pazopanib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Yttrium-90 × NET × 90 days × Clear all

NCT04339036 2026-06-04

CapTemY90

Abramson Cancer Center at Penn Medicine

Phase 2 Recruiting

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡